{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T06:23:32Z","timestamp":1793255012447,"version":"4.5.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T00:00:00Z","timestamp":1688688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T00:00:00Z","timestamp":1688688000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Small-cell lung cancer (SCLC) is a highly aggressive malignancy comprising approximately 15% of lung cancers. Only one-third of patients are diagnosed at limited-stage (LS). Surgical resection can be curative in early stages, followed by platinum\u2013etoposide adjuvant therapy, although only a minority of patients with SCLC qualify for surgery. Concurrent chemo-radiotherapy is the standard of care for LS-SCLC that is not surgically resectable, followed by prophylactic cranial irradiation (PCI) for patients without progression. For extensive-stage (ES)-SCLC, a combination of platinum and etoposide has historically been a mainstay of treatment. Recently, the efficacy of programmed death-ligand 1 inhibitors combined with chemotherapy has become the new front-line standard of care for ES-SCLC. Emerging knowledge regarding SCLC biology, including genomic characterization and molecular subtyping, and new treatment approaches will potentially lead to advances in SCLC patient care.<\/jats:p>","DOI":"10.1007\/s12094-023-03216-3","type":"journal-article","created":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T09:01:45Z","timestamp":1688720505000},"page":"2679-2691","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022)"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2113-1504","authenticated-orcid":false,"given":"Rosario","family":"Garc\u00eda-Campelo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0434-3436","authenticated-orcid":false,"given":"Ivana","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edurne","family":"Arriola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia","family":"Insa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Juan Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Cruz-Castellanos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Mor\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noem\u00ed","family":"Reguart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Zugazagoitia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"D\u00f3mine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,7]]},"reference":[{"key":"3216_CR1","unstructured":"Lung Cancer\u2014Small Cell: Statistics. Available at https:\/\/www.cancernet\/cancer-types\/lung-cancer-small-cell\/statistics. Accessed 15 Sep 2022"},{"key":"3216_CR2","unstructured":"EU\/3\/21\/2415: Orphan designation for the treatment of small cell lung cancer. Available at https:\/\/www.emaeuropaeu\/en\/medicines\/human\/orphan-designations\/eu-3-21-2415. Accessed 15 Sep 2022"},{"key":"3216_CR3","doi-asserted-by":"publisher","first-page":"10131","DOI":"10.2147\/IJGM.S342009","volume":"14","author":"N Li","year":"2021","unstructured":"Li N, Chu Y, Song Q. Brain metastasis in patients with small cell lung cancer. Int J Gen Med. 2021;14:10131\u20139.","journal-title":"Int J Gen Med"},{"issue":"12","key":"3216_CR4","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.1002\/cncr.24314","volume":"115","author":"NR Foster","year":"2009","unstructured":"Foster NR, Mandrekar SJ, Schild SE, Nelson GD, Rowland KM Jr, Deming RL, et al. Prognostic factors differ by tumor stage for small cell lung cancer: a pooled analysis of North central cancer treatment group trials. Cancer. 2009;115(12):2721\u201331.","journal-title":"Cancer"},{"issue":"8","key":"3216_CR5","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/S1470-2045(17)30318-2","volume":"18","author":"C Faivre-Finn","year":"2017","unstructured":"Faivre-Finn C, Snee M, Ashcroft L, Appel W, Barlesi F, Bhatnagar A, et al. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Lancet Oncol. 2017;18(8):1116\u201325.","journal-title":"Lancet Oncol"},{"issue":"6","key":"3216_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0251761","volume":"16","author":"F Franco","year":"2021","unstructured":"Franco F, Carcereny E, Guirado M, Ortega AL, Lopez-Castro R, Rodriguez-Abreu D, et al. Epidemiology, treatment, and survival in small cell lung cancer in Spain: data from the thoracic tumor registry. PLoS\u00a0One. 2021;16(6): e0251761.","journal-title":"PLoS\u00a0One"},{"issue":"2","key":"3216_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100408","volume":"7","author":"L Paz-Ares","year":"2022","unstructured":"Paz-Ares L, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, et al. Durvalumab, with or without tremelimumab, plus platinum\u2013etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN. ESMO Open. 2022;7(2): 100408.","journal-title":"ESMO Open"},{"issue":"1","key":"3216_CR8","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1097\/JTO.0b013e31819140fb","volume":"4","author":"S-HI Ou","year":"2009","unstructured":"Ou S-HI, Ziogas A, Zell JA. Prognostic factors for survival in extensive stage small cell lung cancer (ED-SCLC): the importance of smoking history, socioeconomic and marital statuses, and ethnicity. J Thorac Oncol. 2009;4(1):37\u201343.","journal-title":"J Thorac Oncol"},{"key":"3216_CR9","first-page":"1","volume":"9","author":"S Sivakumar","year":"2022","unstructured":"Sivakumar S, Moore JA, Montesion M, Sharaf R, Lin DI, Fleishmann Z, et al. Integrative analysis of a large real-world cohort of small cell lung cancer identifies distinct genetic subtypes and insights into histological transformation. bioRxiv. 2022;9:1.","journal-title":"bioRxiv"},{"issue":"28","key":"3216_CR10","doi-asserted-by":"publisher","first-page":"4539","DOI":"10.1200\/JCO.2005.04.4859","volume":"24","author":"R Govindan","year":"2006","unstructured":"Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 2006;24(28):4539\u201344.","journal-title":"J Clin Oncol"},{"issue":"9","key":"3216_CR11","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1097\/JTO.0000000000000663","volume":"10","author":"WD Travis","year":"2015","unstructured":"Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG. WHO classification of tumours of the lung, pleura, thymus and heart Lyon: International agency for research on cancer. J Thorac Oncol. 2015;10(9):1240\u20132.","journal-title":"J Thorac Oncol"},{"key":"3216_CR12","first-page":"1","volume-title":"American joint committee on cancer (AJCC) cancer staging manual","author":"MB Amin","year":"2016","unstructured":"Amin MB, Greene FL, Byrd DR, Edge SB, Compton CC, Gershenwald JE, et al. American joint committee on cancer (AJCC) cancer staging manual. 8th ed. New York: Springer; 2016. p. 1\u20131024.","edition":"8"},{"issue":"10","key":"3216_CR13","doi-asserted-by":"publisher","first-page":"3576","DOI":"10.21037\/jtd.2017.09.43","volume":"9","author":"V Ernani","year":"2017","unstructured":"Ernani V, Ganti AK. Surgery for limited-stage small cell lung cancer: ready for prime-time? J Thorac Dis. 2017;9(10):3576\u20138.","journal-title":"J Thorac Dis"},{"issue":"4","key":"3216_CR14","first-page":"CD011917","volume":"4","author":"H Barnes","year":"2017","unstructured":"Barnes H, See K, Barnett S, Manser R. Surgery for limited-stage small-cell lung cancer. Cochrane Database Syst Rev. 2017;4(4):CD011917.","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"3216_CR15","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.cllc.2017.03.009","volume":"18","author":"V Verma","year":"2017","unstructured":"Verma V, Simone CB 2nd, Allen PK, Lin SH. Outcomes of stereotactic body radiotherapy for T1\u2013T2N0 small cell carcinoma according to addition of chemotherapy and prophylactic cranial irradiation: a multicenter analysis. Clin Lung Cancer. 2017;18(6):675-681.e1.","journal-title":"Clin Lung Cancer"},{"issue":"2","key":"3216_CR16","doi-asserted-by":"publisher","first-page":"433","DOI":"10.7150\/jca.21465","volume":"9","author":"Y Yang","year":"2018","unstructured":"Yang Y, Zhang D, Zhou X, Bao W, Ji Y, Sheng L, et al. Prophylactic cranial irradiation in resected small cell lung cancer: a systematic review with meta-analysis. J Cancer. 2018;9(2):433\u20139.","journal-title":"J Cancer"},{"issue":"4","key":"3216_CR17","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1056\/NEJM199901283400403","volume":"340","author":"AT Turrisi","year":"1999","unstructured":"Turrisi AT, Kim K, Blum R, Sause WT, Livingston RB, Komaki R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 1999;340(4):265\u201371.","journal-title":"N Engl J Med"},{"issue":"1","key":"3216_CR18","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S0169-5002(00)00127-6","volume":"30","author":"C Mascaux","year":"2000","unstructured":"Mascaux C, Paesmans M, Berghmans T, Branlen F, Lafitte JJ, Lemaitre F, et al. A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung Cancer. 2000;30(1):23\u201336.","journal-title":"Lung Cancer"},{"issue":"14","key":"3216_CR19","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1200\/JCO.2011.40.4905","volume":"30","author":"A Rossi","year":"2012","unstructured":"Rossi A, Di Maio M, Chiodini P, Rudd RM, Okamoto H, Skarlos DV, et al. Carboplatin-or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol. 2012;30(14):1692\u20138.","journal-title":"J Clin Oncol"},{"issue":"2","key":"3216_CR20","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1179\/joc.1998.10.2.136","volume":"10","author":"M Veslemes","year":"1998","unstructured":"Veslemes M, Polyzos A, Latsi P, Dimitroulis J, Stamatiadis D, Dardoufas C, et al. Optimal duration of chemotherapy in small cell lung cancer: a randomized study of 4 versus 6 cycles of cisplatin-etoposide. J Chemother. 1998;10(2):136\u201340.","journal-title":"J Chemother"},{"key":"3216_CR21","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1056\/NEJM199312163292504","volume":"329","author":"R Arriagada","year":"1993","unstructured":"Arriagada R, Le Chevalier T, Pignon JP, Riviere A, Monnet I, Tuchais C, et al. Initial chemotherapeutic doses and long-term survival in limited small-cell lung cancer. N Engl J Med. 1993;329:1848\u201352.","journal-title":"N Engl J Med"},{"issue":"10","key":"3216_CR22","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1093\/annonc\/mdw263","volume":"27","author":"D De Ruysscher","year":"2016","unstructured":"De Ruysscher D, Lueza B, Le Pechoux C, Johnson DH, O\u2019Brien M, Murray N, et al. Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis. Ann Oncol. 2016;27(10):1818\u201328.","journal-title":"Ann Oncol"},{"issue":"8","key":"3216_CR23","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1093\/annonc\/mdt140","volume":"24","author":"JM Sun","year":"2013","unstructured":"Sun JM, Ahn YC, Choi EK, Ahn MJ, Ahn JS, Lee SH, et al. Phase III trial of concurrent thoracic radiotherapy with either first- or third-cycle chemotherapy for limited-disease small-cell lung cancer. Ann Oncol. 2013;24(8):2088\u201392.","journal-title":"Ann Oncol"},{"issue":"7","key":"3216_CR24","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.annonc.2021.03.207","volume":"32","author":"AC Dingemans","year":"2021","unstructured":"Dingemans AC, Fruh M, Ardizzoni A, Besse B, Faivre-Finn C, Hendriks LE, et al. Small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up(). Ann Oncol. 2021;32(7):839\u201353.","journal-title":"Ann Oncol"},{"issue":"1","key":"3216_CR25","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.lungcan.2011.09.015","volume":"76","author":"R Colaco","year":"2012","unstructured":"Colaco R, Sheikh H, Lorigan P, Blackhall F, Hulse P, Califano R, et al. Omitting elective nodal irradiation during thoracic irradiation in limited-stage small cell lung cancer\u2013evidence from a phase II trial. Lung Cancer. 2012;76(1):72\u20137.","journal-title":"Lung Cancer"},{"issue":"7","key":"3216_CR26","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1056\/NEJM199908123410703","volume":"341","author":"A Auperin","year":"1999","unstructured":"Auperin A, Arriagada R, Pignon JP, Le Pechoux C, Gregor A, Stephens RJ, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic cranial irradiation overview collaborative group. N Engl J Med. 1999;341(7):476\u201384.","journal-title":"N Engl J Med"},{"issue":"5","key":"3216_CR27","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S1470-2045(09)70101-9","volume":"10","author":"C Le Pechoux","year":"2009","unstructured":"Le Pechoux C, Dunant A, Senan S, Wolfson A, Quoix E, Faivre-Finn C, et al. Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99\u201301, EORTC 22003\u201308004, RTOG 0212, and IFCT 99\u201301): a randomised clinical trial. Lancet Oncol. 2009;10(5):467\u201374.","journal-title":"Lancet Oncol"},{"issue":"5","key":"3216_CR28","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/j.jtho.2020.12.024","volume":"16","author":"JSA Belderbos","year":"2021","unstructured":"Belderbos JSA, De Ruysscher DKM, De Jaeger K, Koppe F, Lambrecht MLF, Lievens YN, et al. Phase 3 randomized trial of prophylactic cranial irradiation with or without hippocampus avoidance in SCLC (NCT01780675). J Thorac Oncol. 2021;16(5):840\u20139.","journal-title":"J Thorac Oncol"},{"issue":"28","key":"3216_CR29","doi-asserted-by":"publisher","first-page":"3118","DOI":"10.1200\/JCO.21.00639","volume":"39","author":"NR de Dios","year":"2021","unstructured":"de Dios NR, Counago F, Murcia-Mejia M, Rico-Oses M, Calvo-Crespo P, Samper P, et al. Randomized phase III trial of prophylactic cranial irradiation with or without hippocampal avoidance for small-cell lung cancer (PREMER): a GICOR-GOECP-SEOR study. J Clin Oncol. 2021;39(28):3118\u201327.","journal-title":"J Clin Oncol"},{"issue":"1","key":"3216_CR30","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.annonc.2021.09.011","volume":"33","author":"S Peters","year":"2022","unstructured":"Peters S, Pujol JL, Dafni U, D\u00f3mine M, Popat S, Reck M, Andrade J, ETOP\/IFCT 4-12 STIMULI Collaborators, et al. Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy\u2014results from the randomised phase II ETOP\/IFCT 4\u201312 STIMULI trial. Ann Oncol. 2022;33(1):67\u201379.","journal-title":"Ann Oncol"},{"issue":"23","key":"3216_CR31","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","volume":"379","author":"L Horn","year":"2018","unstructured":"Horn L, Mansfield AS, Szcz\u0119sna A, Havel L, Krzakowski M, Hochmair MJ, IMpower133 Study Group, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379(23):2220\u20139.","journal-title":"N Engl J Med"},{"issue":"1","key":"3216_CR32","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","volume":"394","author":"L Paz-Ares","year":"2019","unstructured":"Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, CASPIAN investigators, et al. Durvalumab plus platinum\u2013etoposide versus platinum\u2013etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394(1):1929\u201339.","journal-title":"Lancet"},{"issue":"21","key":"3216_CR33","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1200\/JCO.20.00793","volume":"38","author":"CM Rudin","year":"2020","unstructured":"Rudin CM, Awad MM, Navarro A, Gottfried M, Peters S, Cs\u0151szi T, KEYNOTE-604 Investigators, et al. Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 study. J Clin Oncol. 2020;38(21):2369\u201379.","journal-title":"J Clin Oncol"},{"issue":"12","key":"3216_CR34","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1001\/jama.2022.16464","volume":"328","author":"Y Cheng","year":"2022","unstructured":"Cheng Y, Han L, Wu L, Chen J, Sun H, Wen G, et al. Effect of First-line serplulimab vs placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer: the ASTRUM-005 randomized clinical trial. JAMA. 2022;328(12):1223\u201332.","journal-title":"JAMA"},{"issue":"6","key":"3216_CR35","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S1470-2045(22)00224-8","volume":"23","author":"J Wang","year":"2022","unstructured":"Wang J, Zhou C, Yao W, Wang Q, Min X, Chen G, CAPSTONE-1 Study Group, et al. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23(6):739\u201347.","journal-title":"Lancet Oncol"},{"issue":"7","key":"3216_CR36","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1200\/JCO.1999.17.7.2092","volume":"17","author":"B Jeremic","year":"1999","unstructured":"Jeremic B, Shibamoto Y, Nikolic N, Milicic B, Milisavljevic S, Dagovic A, et al. Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: a randomized study. J Clin Oncol. 1999;17(7):2092\u20139.","journal-title":"J Clin Oncol"},{"issue":"9962","key":"3216_CR37","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/S0140-6736(14)61085-0","volume":"385","author":"BJ Slotman","year":"2015","unstructured":"Slotman BJ, van Tinteren H, Praag JO, Knegjens JL, El Sharouni SY, Hatton M, et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lancet. 2015;385(9962):36\u201342.","journal-title":"Lancet"},{"key":"3216_CR38","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.lungcan.2017.03.007","volume":"108","author":"BJ Slotman","year":"2017","unstructured":"Slotman BJ, Faivre-Finn C, van Tinteren H, Keijser A, Praag J, Knegjens J, et al. Which patients with ES-SCLC are most likely to benefit from more aggressive radiotherapy: a secondary analysis of the phase III CREST trial. Lung Cancer. 2017;108:150\u20133.","journal-title":"Lung Cancer"},{"issue":"4","key":"3216_CR39","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.cllc.2015.09.007","volume":"17","author":"DA Palma","year":"2016","unstructured":"Palma DA, Warner A, Louie AV, Senan S, Slotman B, Rodrigues GB. Thoracic radiotherapy for extensive stage small-cell lung cancer: a meta-analysis. Clin Lung Cancer. 2016;17(4):239\u201344.","journal-title":"Clin Lung Cancer"},{"key":"3216_CR40","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.ejca.2019.01.003","volume":"110","author":"S Rathod","year":"2019","unstructured":"Rathod S, Jeremic B, Dubey A, Giuliani M, Bashir B, Chowdhury A, et al. Role of thoracic consolidation radiation in extensive stage small cell lung cancer: a systematic review and meta-analysis of randomised controlled trials. Eur J Cancer. 2019;110:110\u20139.","journal-title":"Eur J Cancer"},{"issue":"7","key":"3216_CR41","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1056\/NEJMoa071780","volume":"357","author":"B Slotman","year":"2007","unstructured":"Slotman B, Faivre-Finn C, Kramer G, Rankin E, Snee M, Hatton M, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med. 2007;357(7):664\u201372.","journal-title":"N Engl J Med"},{"issue":"5","key":"3216_CR42","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S1470-2045(17)30230-9","volume":"18","author":"T Takahashi","year":"2017","unstructured":"Takahashi T, Yamanaka T, Seto T, Harada H, Nokihara H, Saka H, et al. Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18(5):663\u201371.","journal-title":"Lancet Oncol"},{"key":"3216_CR43","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.lungcan.2016.09.010","volume":"101","author":"D Bernhardt","year":"2016","unstructured":"Bernhardt D, Bozorgmehr F, Adeberg S, Opfermann N, von Eiff D, Rieber J, et al. Outcome in patients with small cell lung cancer re-irradiated for brain metastases after prior prophylactic cranial irradiation. Lung Cancer. 2016;101:76\u201381.","journal-title":"Lung Cancer"},{"issue":"3","key":"3216_CR44","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/j.ijrobp.2011.01.001","volume":"81","author":"RE Wegner","year":"2011","unstructured":"Wegner RE, Olson AC, Kondziolka D, Niranjan A, Lundsford LD, Flickinger JC. Stereotactic radiosurgery for patients with brain metastases from small cell lung cancer. Int J Radiat Oncol Biol Phys. 2011;81(3):e21\u20137.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"3216_CR45","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1001\/jamaoncol.2020.1271","volume":"6","author":"CG Rusthoven","year":"2020","unstructured":"Rusthoven CG, Yamamoto M, Bernhardt D, Smith DE, Gao D, Serizawa T, et al. Evaluation of first-line radiosurgery vs whole-brain radiotherapy for small cell lung cancer brain metastases: the FIRE-SCLC Cohort Study. JAMA Oncol. 2020;6(7):1028\u201337.","journal-title":"JAMA Oncol"},{"issue":"5","key":"3216_CR46","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1097\/JTO.0b013e31824c7f4b","volume":"7","author":"TK Owonikoko","year":"2012","unstructured":"Owonikoko TK, Behera M, Chen Z, Bhimani C, Curran WJ, Khuri FR, et al. A systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory small-cell lung cancer. J Thorac Oncol. 2012;7(5):866\u201372.","journal-title":"J Thorac Oncol"},{"issue":"34","key":"3216_CR47","doi-asserted-by":"publisher","first-page":"5441","DOI":"10.1200\/JCO.2006.06.5821","volume":"24","author":"MER O\u2019Brien","year":"2006","unstructured":"O\u2019Brien MER, Ciuleanu TE, Tsekov H, Shparyk Y, \u010cu\u010devi\u00e1 B, Juhasz G, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol. 2006;24(34):5441\u20137.","journal-title":"J Clin Oncol"},{"issue":"2","key":"3216_CR48","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1200\/JCO.1999.17.2.658","volume":"17","author":"J von Pawel","year":"1999","unstructured":"von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chrysson NG, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol. 1999;17(2):658\u201367.","journal-title":"J Clin Oncol"},{"issue":"6","key":"3216_CR49","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1200\/JCO.21.01881","volume":"40","author":"J Zugazagoitia","year":"2022","unstructured":"Zugazagoitia J, Paz-ares L. Extensive-stage small-cell lung cancer: first-line and second-line treatment options. J Clin Oncol. 2022;40(6):671\u201381.","journal-title":"J Clin Oncol"},{"issue":"5","key":"3216_CR50","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/S1470-2045(20)30068-1","volume":"21","author":"J Trigo","year":"2020","unstructured":"Trigo J, Subbiah V, Besse B, Moreno V, L\u00f3pez R, Sala MA, et al. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. Lancet Oncol. 2020;21(5):645\u201354.","journal-title":"Lancet Oncol"},{"issue":"10","key":"3216_CR51","doi-asserted-by":"publisher","first-page":"S844","DOI":"10.1016\/j.jtho.2021.08.030","volume":"16","author":"L Paz-Ares","year":"2021","unstructured":"Paz-Ares L, Ciuleanu T, Navarro A, Fulop A, Cousin S, Bonanno L, et al. PL02.03 lurbinectedin\/doxorubicin versus CAV or topotecan in relapsed SCLC patients: phase III randomized ATLANTIS Trial. J Thorac Oncol. 2021;16(10):S844\u20135.","journal-title":"J Thorac Oncol"},{"issue":"7","key":"3216_CR52","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/S1470-2045(16)30098-5","volume":"17","author":"SJ Antonia","year":"2016","unstructured":"Antonia SJ, L\u00f3pez-Martin JA, Bendell J, Ott PA, Taylor M, Eder JP, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1\/2 trial. Lancet Oncol. 2016;17(7):883\u201395.","journal-title":"Lancet Oncol"},{"issue":"4","key":"3216_CR53","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.jtho.2019.12.109","volume":"15","author":"HC Chung","year":"2020","unstructured":"Chung HC, Piha-Paul SA, Lopez-Martin J, Schellens JHM, Kao S, Miller WH, et al. Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC: results from the KEYNOTE-028 and KEYNOTE-158 studies. J Thorac Oncol. 2020;15(4):618\u201327.","journal-title":"J Thorac Oncol"},{"issue":"5","key":"3216_CR54","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.annonc.2021.01.071","volume":"32","author":"DR Spigel","year":"2021","unstructured":"Spigel DR, Vicente D, Ciuleanu TE, Gettinger S, Peters S, Horn L, et al. Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331. Ann Oncol. 2021;32(5):631\u201341.","journal-title":"Ann Oncol"},{"key":"3216_CR55","first-page":"J2202823","volume":"23","author":"L Paz Ares","year":"2023","unstructured":"Paz Ares L, Champiat S, Lai WV, Izumi H, Govindan R, Boyer M, et al. Tarlatamab, a first-in-class DLL3-targeted biespecific T-Cell engager, in recurrent small cell lung cancer: an open-label phase I study. J Clin Oncol. 2023;23:J2202823.","journal-title":"J Clin Oncol"},{"key":"3216_CR56","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1200\/JCO.2018.77.7672","volume":"36","author":"MC Pietanza","year":"2018","unstructured":"Pietanza MC, Waqar SN, Krug LM, Dowlati A, Hann CL, Chiappori A, et al. Randomized, double-blind, phase II study of temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer. J Clin Oncol. 2018;36:2386\u201394.","journal-title":"J Clin Oncol"},{"issue":"10","key":"3216_CR57","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1158\/2159-8290.CD-19-0582","volume":"9","author":"AF Farago","year":"2019","unstructured":"Farago AF, Yeap BY, Stanzione M, Hung YP, Heist RS, Marcoux JP, et al. Combination olaparib and temozolomide in relapsed small-cell lung cancer. Cancer Discov. 2019;9(10):1372\u201387.","journal-title":"Cancer Discov"},{"issue":"suppl_7","key":"3216_CR58","first-page":"S197","volume":"33","author":"T Doi","year":"2022","unstructured":"Doi T, Patel M, Falchook GS, Koyama T, Friedman CF, Piha-Poul S, et al. DS-7300 (B7-H3 DXd antibody-drug conjugate [ADC]) shows durable antitumor activity in advanced solid tumors: extended follow-up of a phase I\/II study. Ann Oncol. 2022;33(suppl_7):S197\u2013224.","journal-title":"Ann Oncol"},{"issue":"1","key":"3216_CR59","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jtho.2018.09.027","volume":"14","author":"M Christodoulou","year":"2019","unstructured":"Christodoulou M, Blackhall F, Mistry H, Leylek A, Knegjens J, Remouchamps V, et al. Compliance and outcome of elderly patients treated in the concurrent once-daily versus twice-daily radiotherapy (CONVERT) trial. J Thorac Oncol. 2019;14(1):63\u201371.","journal-title":"J Thorac Oncol"},{"issue":"4","key":"3216_CR60","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1002\/cncr.32586","volume":"126","author":"X Hu","year":"2020","unstructured":"Hu X, Bao Y, Jin XY, Neng ZH, Shi LJ, Zhang L, et al. Final report of a prospective randomized study on thoracic radiotherapy target volume for limited-stage small cell lung cancer with radiation dosimetric analyses. Cancer. 2020;126(4):840\u20139.","journal-title":"Cancer"},{"issue":"5","key":"3216_CR61","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.cllc.2021.03.010","volume":"22","author":"J Weiss","year":"2021","unstructured":"Weiss J, Goldschmidt J, Andric Z, Dragnev KH, Gwaltney C, Skaltsa K, et al. Effects of trilaciclib on chemotherapy-induced myelosuppression and patient-reported outcomes in patients with extensive-stage small cell lung cancer: pooled results from three phase II randomized, double-blind, placebo-controlled studies. Clin Lung Cancer. 2021;22(5):449\u201360.","journal-title":"Clin Lung Cancer"}],"updated-by":[{"DOI":"10.1007\/s12094-023-03290-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T00:00:00Z","timestamp":1691539200000}}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-023-03216-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-023-03216-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-023-03216-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T08:14:24Z","timestamp":1692000864000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-023-03216-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,7]]},"references-count":61,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["3216"],"URL":"https:\/\/doi.org\/10.1007\/s12094-023-03216-3","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,7]]},"assertion":[{"value":"8 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s12094-023-03290-7","URL":"https:\/\/doi.org\/10.1007\/s12094-023-03290-7","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"RGC reports Advisory boards, Consultancy and Speaker honoraria from MSD, BMS, Roche, Boehringer Ingelheim, Pfizer, Novartis, AstraZeneca, Lilly, Takea and Amgen. IS reports Advisory Board from Roche, Novartis, Boehringer Ingelheim, Takeda and Sanofi; Speaker from Roche, MSD, Pfizer, BMS and AstraZeneca; Grant from Roche, Takeda, Pfizer, BMS and AstraZeneca; Non-financial Support from Member of GECP. EA reports Advisory Board, Speakerand Grant from Roche; Advisory Board and Speaker from Astra Zeneca and BMS; Advisory Board, Speaker and Non-financial Support from Takeda; Advisory Board from Lilly and Boehringer-Ingelheim; Speaker from MSD, Merck, Thermo Fisher Scientific and Guardant Health; Speaker and- Non-financial Support from Pfizer. AI reports Advisory Board and Speaker from Roche, AstraZeneca and Sanofi; Speaker from Takeda and BMS. OJJV reports Advisory Board and Speaker from BMS and Janssen; Speker from Roche; Advisory Board, Speaker and Other from AstraZeneca, Takeda and Janssen; Advisory Board from Lilly. NR reports Advisory Board, Speaker and- Other from MSD; Advisory Board and Speaker from AstraZeneca, Takeda, Amgen, Lilly, Sanofi, Roche and Janssen. JZ reports Speaker, Grant and Personal Feels from BMS and AstraZencea; Advisory Board and Personal Feels from Sanofi; Speaker from MSD; Grant and Personal Feels from Roche; Speaker and Personal Feels from Pfizer; Advisory Board from Novartis and Speaker from NanoString. MD reports Advisory Board and Speaker from AatraZeneca, Pfizer and Takeda; Speaker from BMS, MSD and Roche; Advisory Board from Janssen and Sanofi. TM and PCC have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Approval from the institutional review board was not required for this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}},{"value":"For this retrospective review, formal consent is not required.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}